Bebtelovimab neutralizes Omicron, including subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus data VANCOUVER, B.C. — AbCellera (Nasdaq: ABCL) today announced Eli Lilly and Company (Lilly) has entered into a… Read More
“Feedback from Canadian biotech companies on the contribution of young workers has been overwhelmingly positive. The Catalyst Award is our way to highlight new hires, showcase their achievements and tell… Read More
Researchers at the University of British Columbia are shedding new light on the molecular factors that give COVID-19 variants a competitive edge – essential knowledge that could improve disease management… Read More
Investigational data from long-term, follow-up studies showed that olipudase alfa provided sustained improvement in lung function (as measured by DLco) and reduction of spleen and liver volumes over time in… Read More
Phase 3 trial reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more… Read More
